Consistent with Da Volterra’s mission to bring innovative medicines to patients, we are focused on enrolling and conducting the clinical trials necessary to demonstrate that our microbiome protectors are safe and efficacious. This will allow Da Volterra to gain regulatory approvals to make our medicines available broadly to patients as quickly as possible.
Da Volterra is not currently accepting requests for Expanded Access / Compassionate Use of DAV132. Clinical trials offer the safest and best opportunity for people to access an investigational product before it is approved by a regulatory agency and placed on market. Please find here a list of our ongoing clinical trials with DAV132 and our other products in development. Da Volterra will regularly evaluate this policy.